TheraCryf Announces Full Year Results and Ox-1 Program Webinar

An update from Evgen Pharma ( (GB:TCF) ) is now available.

TheraCryf plc has announced the release of its full year results for the year ending 31 March 2025, scheduled for 3 June 2025, with a live presentation by key executives. Additionally, the company will host a webinar on 11 June 2025 to provide an in-depth look at its Ox-1 addiction program, reflecting its focus on advancing its clinical pipeline and engaging with investors. These events are open to existing and potential shareholders, indicating TheraCryf’s commitment to transparency and stakeholder engagement.

Spark’s Take on GB:TCF Stock

According to Spark, TipRanks’ AI Analyst, GB:TCF is a Neutral.

Evgen Pharma’s overall stock score of 49 reflects ongoing financial and operational challenges, including declining revenues and losses. While the technical analysis shows mixed momentum, recent corporate events provide a positive outlook with strategic initiatives aimed at improving financial stability and advancing key drug development programs.

To see Spark’s full report on GB:TCF stock, click here.

More about Evgen Pharma

TheraCryf plc is a clinical stage drug development company focused on brain disorders, including addiction, anxiety, fatigue, narcolepsy, glioblastoma, and neurodevelopmental disorders. The company aims to generate compelling data sets to achieve preclinical and clinical proof of concept, partnering with mid-size to large pharmaceutical companies for larger trials and commercialization. TheraCryf has industry partnerships and collaborations with major universities and hospitals, and is headquartered in Alderley Park, Cheshire, trading on AIM in London under the ticker symbol TCF.

Average Trading Volume: 3,996,669

Technical Sentiment Signal: Sell

Current Market Cap: £5.05M

See more data about TCF stock on TipRanks’ Stock Analysis page.